Dystrophin expressing chimeric cells - Dystrogen Therapeutics
Alternative Names: DEC; DT-DEC01; Duchenne muscular dystrophy cell therapy - Dystrogen TherapeuticsLatest Information Update: 28 Feb 2025
At a glance
- Originator University of Illinois at Chicago
- Developer Dystrogen Therapeutics
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Duchenne muscular dystrophy
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for phase-I development in Duchenne muscular dystrophy(In adolescents, In children) in European Union (Parenteral)
- 26 Sep 2022 Efficacy data from a phase I trial in Duchenne Muscular Dystrophy released by Dystrogen Therapeutics
- 04 Jan 2022 Phase-I clinical trials in Duchenne muscular dystrophy (In children, In adolescents) in USA (Parenteral)